On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management increased its position in Nektar Therapeutics by 180,367 shares. The estimated value of the additional shares is $10.27 million, calculated using the average closing price for the quarter ending March 31, 2026. The quarter-end value of the firm’s Nektar Therapeutics stake rose by $29.43 million, a figure that includes both trading activity and share price appreciation.
What else to know
-
Prosight Management was a net buyer in Nektar Therapeutics this quarter. The post-trade stake accounted for 8.67% of its 13F reportable AUM.
-
Top five fund holdings after the filing:
-
NASDAQ: NKTR: $52.88 million (8.7% of AUM)
-
NYSE: BSX: $49.92 million (8.2% of AUM)
-
NASDAQ: JANX: $49.34 million (8.1% of AUM)
-
NASDAQ: PRCT: $48.64 million (8.0% of AUM)
-
NASDAQ: LKFT: $46.50 million (7.6% of AUM)
-
-
As of May 14, 2026, shares of Nektar Therapeutics were priced at $66.61, up nearly 600% over the past year and significantly outperforming the S&P 500, which is instead up about 28%.
Company overview
|
Metric |
Value |
|---|---|
|
Price (as of Friday) |
$66.61 |
|
Market capitalization |
$2.25 billion |
|
Revenue (TTM) |
$55.63 million |
|
Net income (TTM) |
($158.10 million) |
Company snapshot
-
Nektar develops biopharmaceutical products targeting unmet medical needs, with a pipeline including Bempegaldesleukin (IL-2 pathway agonist), NKTR-358 (cytokine Treg stimulant), and NKTR-255 (IL-15 receptor agonist), among others.
-
The firm operates a research-driven business model focused on drug discovery, clinical development, and strategic collaborations with major pharmaceutical companies to generate revenue through licensing, milestones, and potential product sales.
-
It serves healthcare providers, hospitals, and pharmaceutical partners, targeting patients with cancer, autoimmune, and inflammatory diseases in the United States and international markets.
Nektar Therapeutics is a biotechnology company specializing in the development of novel therapeutics for oncology and immunology indications. The company leverages proprietary drug discovery platforms and strategic partnerships to advance a diverse clinical pipeline. Its focus on innovative biologics and collaborative R&D positions it to address significant unmet needs in the global healthcare market.
What this transaction means for investors
Nektar stock has already delivered eye-popping gains over the past year, yet Prosight still chose to add to what has become its largest disclosed position. With that in mind, the purchase ultimately looks like a vote of confidence in Nektar as it approaches a make-or-break stretch of clinical development.
Meanwhile, the core story remains rezpegaldesleukin, Nektar’s experimental treatment for autoimmune diseases. Management recently reported encouraging long-term data in both atopic dermatitis and alopecia areata and expects to begin its Phase 3 ZENITH-AD program by July. The company also plans an End-of-Phase 2 meeting with the FDA for alopecia areata this quarter.
Financially, Nektar appears far better positioned than many clinical-stage biotech peers. First-quarter revenue rose to $10.9 million from $10.5 million one year prior, while cash and marketable securities reached $731.6 million at quarter-end. Management noted that the figure excludes roughly $351 million of net proceeds from an April stock offering, giving the company more than $1 billion in liquidity to fund development.
Ultimately, if rezpegaldesleukin succeeds in late-stage trials, today’s valuation could look conservative, but if it stumbles, much of the recent rally could quickly unwind. Prosight’s purchase suggests it believes the odds favor the former.
